TRIPTODUR KIT Drug Patent Profile

Which patents cover Triptodur Kit, and what generic alternatives are available?

Triptodur Kit is a drug marketed by Azurity and is included in one NDA. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the triptorelin pamoate profile page.

DrugPatentWatch^® Generic Entry Outlook for Triptodur Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 30, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TRIPTODUR KIT

International Patents:	47
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	TRIPTODUR KIT at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRIPTODUR KIT

NDA:

208956

Dosage:

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TRIPTODUR KIT

TRIPTODUR KIT is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	TRIPTODUR KIT	triptorelin pamoate	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	208956-001	Jun 29, 2017		RX	Yes	Yes			Y

International Patents for TRIPTODUR KIT

When does loss-of-exclusivity occur for TRIPTODUR KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Australia

Brazil

Canada

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIPTODUR KIT around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	3000
Australia	2008259411
Brazil	PI0812250
Canada	2688478
China	101677959

Last updated: June 29, 2026

TRIPTODUR KIT (Triptorelin) Market Dynamics and Financial Trajectory: Sales, Pricing, Exclusivity, and Competitive Risks

Executive summary: TRIPTODUR KIT is a brand of triptorelin (long-acting injectable) marketed in the US for prostate cancer (and historically for other indications outside the US). The product’s financial trajectory is driven by (1) loss-of-exclusivity timing for patent and regulatory exclusivities, (2) channel inventory and wholesaler buying cycles typical for oncology injectables, (3) payer adoption and prior authorization friction versus oral alternatives in advanced disease settings, and (4) competitive pressure from other GnRH agonists and long-acting formulations. A usable, investment-grade view of sales, pricing, and forecast risk requires primary data from company disclosures and/or IQVIA/DRUG/GoodRx-style pricing sources plus Orange Book and FDA labeling status. Without those sourced inputs, a complete and accurate financial trajectory and market-dynamics assessment cannot be produced.

What is TRIPTODUR KIT and what therapeutic market does it compete in?

Featured snippet answer: TRIPTODUR KIT is a long-acting triptorelin injectable marketed in the oncology (hormone-sensitive prostate cancer / advanced prostate cancer) space in the US.

How TRIPTODUR KIT is used clinically

• Long-acting GnRH agonist class positioned to reduce testosterone via sustained pituitary suppression.
• Real-world prescribing is strongly shaped by stage of disease, urology and oncology practice patterns, and local payer rules.

What competitors matter for market dynamics

• Competitive set is typically other GnRH agonists and long-acting injectables, with market share influenced by:
  • dosing interval convenience,
  • wastage and administration workflow,
  • payer contracts and preferred drug lists,
  • patient affordability and access.

How strong is TRIPTODUR KIT’s patent and exclusivity protection for US launch defense?

Featured snippet answer: A correct defense assessment depends on Orange Book listings (patent numbers, listed drug versions, patent expiry dates) and exclusivity periods tied to the application. That data is not provided here, so a complete US exclusivity and patent-protection map cannot be compiled.

What determines “time-to-generic” for TRIPTODUR KIT

• Orange Book expiration (composition, formulation, method-of-use, and device/packaging patents where applicable).
• FDA exclusivity (if any) tied to the approval pathway and supplemental approvals.
• Practical generic entry barriers:
  • complex depot formulation manufacturing,
  • sterility and particle-size control,
  • bioequivalence strategy for long-acting depots,
  • device or kit configuration constraints.

When does TRIPTODUR KIT lose exclusivity and what are Paragraph IV generic risk windows?

Featured snippet answer: A Paragraph IV risk window is calculated from the earliest Orange Book expiration plus any exclusivity offsets. No Orange Book expiry dataset is included, so exact windows and generic entry scenarios cannot be stated.

What to model in exclusivity timing for long-acting injectables

• Earliest expiry governs first potential 505(b)(2) “same as” changes and generic launch.
• Later expiry of formulation or method patents pushes authorized generics and “skinny label” shifts.

What is the Orange Book status of TRIPTODUR KIT?

Featured snippet answer: Orange Book status is defined by the FDA-listed patents and exclusivity identifiers for the specific NDC(s) and presentation. This information is not provided, so the Orange Book table cannot be generated.

What an Orange Book table must include

• Patent number
• Patent type (composition, method, formulation, other)
• Listed drug (NDC and strength/presentation)
• Expiration date
• Any pediatric exclusivity or patent term adjustments
• Exclusivity type tied to the NDA (if applicable)

How does TRIPTODUR KIT pricing and reimbursement evolve in US oncology formularies?

Featured snippet answer: For injectable oncology products, pricing is typically stabilized by contract rebates and preferred formulary status, then declines post-preference loss or when generics/authorized substitutes appear. A specific pricing trajectory for TRIPTODUR KIT requires payer and channel data not included here.

The main pricing levers that move revenue

• Manufacturer list price changes versus net price after rebates.
• State and federal contracting differences (Medicare Part D, commercial plan tiers).
• Hospital outpatient vs physician office administration reimbursement differences.
• Prior authorization and step therapy rules tied to prostate cancer staging.

What has been TRIPTODUR KIT’s sales trajectory (revenue, unit trends, and channel demand)?

Featured snippet answer: A quantified sales trajectory requires company financial statements and/or third-party sales telemetry. No TRIPTODUR KIT revenue/unit dataset is present, so the sales timeline cannot be produced.

What “financial trajectory” should track for a depot injectable

• Annual US net sales
• Unit shipments (kits) and average selling price proxies
• Quarter-by-quarter variability around patient starts
• Refill inertia and substitution timing at the patient level

What generic entry risks exist for TRIPTODUR KIT and how would launch scenarios play out?

Featured snippet answer: Generic entry risk is driven by:

1. patent expiry and exclusivity status,
2. injectable depot formulation barriers,
3. likelihood and timing of ANDA filings,
4. settlement or consent judgment outcomes. Those inputs are not provided, so launch scenarios cannot be mapped.

Typical generic playbook for long-acting depots

• ANDA with bioequivalence strategy aligned to depot pharmacokinetics.
• Potential design-around:
  • formulation differences that avoid infringement (while meeting release-rate and PK criteria)
  • alternative manufacturing controls within the allowable patent space.

What patent litigation affects TRIPTODUR KIT market timing and generic substitution?

Featured snippet answer: Litigation timelines materially affect generic entry dates through automatic stays, consent decrees, and commercial launch delays. Specific TRIPTODUR KIT litigation records are not supplied, so litigation impacts cannot be stated.

What to document in litigation-based market-dynamics modeling

• Case numbers and venues
• Filing dates for ANDA or counterclaims
• Court rulings and stay expiration dates
• Settlement terms if disclosed (authorized generic, market-share protection, or milestone payments)

How does TRIPTODUR KIT compare with other triptorelin and GnRH agonist products on market exposure?

Featured snippet answer: Competitor comparisons depend on product-level:

• FDA status,
• dosing interval,
• NDC availability,
• payer preference,
• contract rebate position,
• and patent headroom of each competing product. No competitor patent or sales datasets are provided, so an apples-to-apples market comparison cannot be completed.

What drives share allocation among GnRH agonists

• Hospital and urology practice procurement.
• Supply reliability and kit availability.
• Patient adherence to clinic scheduling (long-acting interval).
• Clinical comfort with specific depot handling and administration.

What commercial inflection points typically change TRIPTODUR KIT revenues?

Featured snippet answer: For long-acting oncology injectables, inflection points usually come from:

• formulary changes,
• patent expirations and generic/authorized generic entry,
• label expansions or safety communications,
• and manufacturing continuity events. Quantification for TRIPTODUR KIT requires missing datasets.

The specific inflection points to map

• FDA labeling revisions that alter patient eligibility.
• Payer policy updates and formulary committee decisions.
• Manufacturer supply events affecting fill rate.

Key Takeaways

• TRIPTODUR KIT is a long-acting triptorelin injectable used in oncology hormone suppression, and its revenue path depends on exclusivity and patent headroom plus payer access dynamics.
• A complete, accurate financial trajectory with dates and quantified market shifts requires Orange Book/NDC-level exclusivity and patent data plus sales telemetry or company financial disclosures, neither of which is present here.
• The practical risk drivers are generic entry timing, litigation stay/settlement outcomes, and formulary preference changes versus other GnRH agonists.

FAQs

1. What factors most strongly affect net price for long-acting injectable oncology products like TRIPTODUR KIT?
2. How do Orange Book patent expirations translate into generic launch timing for depot formulations?
3. What are the main regulatory pathways (ANDA vs 505(b)(2)) that could enable TRIPTODUR KIT substitution?
4. How do payer prior authorization and formulary tier placement typically shift demand for GnRH agonists?
5. What litigation events most often delay generic entry for injectable drug products?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-29).